Roche reports good news in breast cancer combo trial
Roche announced that a Phase III trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Abraxane | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Pharmaceuticals